Navigation Links
Theory of How HIV Attacks is Wrong: Study

A popular theory on how HIV attacks the body's immune system is wrong, a new study has found.

Scientists have long believed that HIV causes the slow depletion of healthy white blood cells -- the T cells which recognize infections so the body can fight them off -- by causing infected T cells to produce virus particles before dying.

This ongoing cycle of infection, HIV production, reinfection and cell destruction has been called the "runaway" hypothesis.

But if this were so, the T cells would be killed off far too quickly, the researchers found.

Using a simple mathematical model, researchers in the United States and Britain showed the "runaway" model would deplete the body's healthy T cells in a matter of months, instead of the years it actually takes.

The results show that a "slow process must be active" in the depletion of the T cells, the authors wrote in the current issue of the journal PLoS Medicine.

Identifying this process "will provide a key insight into the nature of HIV disease and indicate potential new approaches to therapy," they concluded.

A potential explanation for the slow process could be that the virus slowly adapts over the course of the infection, the authors said.

"The virus is constantly mutating and there may be selection - in a Darwinian sense -- over time for 'fitter' mutants of the virus in an infected person," said lead author Andrew Yates of Emory University in Atlanta, Georgia.

"There are several ways the virus could become fitter - for example by being able to infect new cells more readily, or by infected cells producing more new virus, or producing it more rapidly," he said in an e-mail interview.

"The virus adaptation hypothesis requires a lot more experimental investigation, however, and is only a tentative conclusion."


'"/>




Page: 1

Related medicine news :

1. New Information On Virus Goes Against The Age-Old Theory
2. Controversial Theory Says DNA Can Be Pushed To "Dark States"
3. Study Refutes Theory on HIVs Effect on White Blood Cells
4. Maths Theory Shows Genetic Pattern of Tumour Growth
5. Heart Attacks during Menstruation!
6. Supply of Radiopharmaceuticals Hampered by Attacks
7. Air Pollution and Heart Attacks
8. Kidney Patients Risk Heart Attacks
9. Kidney Patients Risk Heart Attacks
10. New Medication May Decrease The Frequency Of Angina Attacks
11. Obese Kids Also Prone To Heart Attacks
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Theory How HIV Attacks Wrong Study

(Date:10/3/2008)...- Inc. Magazine recently included,Connolly Consult...ing,private companies in the country. The list is ...segment of the economy -- America,s,independent-mi...ies,represent the backbone of the U.S. economy., ...03/NY36880LOGO ), Connolly Consulting,s consiste...
(Date:10/3/2008)... Discrimination; Recognizes,Importance of Mental H.../PRNewswire-USNewswire/ -- Mental Health,America t...approval of a,mental health parity legislation tha...ion against Americans with mental health and subst...lans., The legislation, which recognizes the impo...
(Date:10/3/2008)...search Foundation(R) Collection of, Bouquets to T...Research, LOS ANGELES, Oct. 3 /PRNewswire/ -- Tel...g only hand-arranged, hand-delivered floral,arrang...nth-long,collaboration with The City of Hope, John... Cancer Center in southern California and national...
(Date:10/3/2008)...- As the population ages, a big,question employers...e the,financial crunch of an illness?", In most c...eck to,paycheck and now need two incomes to provid... spouses becomes critically ill and unable to work...ut the healthy,employee/spouse is strained by the ...
Breaking Medicine News(10 mins):Health News:Connolly Consulting Makes the 2008 Inc. Magazine's List of America's 5000 Fastest Growing Companies 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 3Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 2Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 3Health News:Can Your Employees Survive the Financial Crunch of an Illness? 2
...s of hand-foot-mouth disease were reported in the ... of disaster relief George Chan Hong Nam said that...e days, bringing this year's total to more than 1,...uld not take this lightly, as the consequences can...
...ing pregnancy and childbirth are less likely to in...ing activities such as playing with their newborns...irst of its kind to analyze the impact of mother’s...practices, post partum. The researchers analyzed ...
...efects is improved by incorporation of folic acid ... known that folic acid supplementation during preg...th defects such as spina bifida, anencephaly etc. ...f consumption of folic acid fortified grains on ne...
... that the dreaded bird flu had made an entry into ...was confirmed that a cat had died of bird flu. Sin...sures to ward off the disease. // Federal Agricult...hofer has said that cats in the region of the bird...
Other Medicine News:Health News:Depressive Mothers Do Not Play Enough With Their Infants 2
(Date:10/2/2008)... STOCKHOLM, October 2 /- Athera Biot...unced today that they have entered into a,collabor...cts for the,prevention or treatment of cardiovascu...lows the recent publication of work by Athera,scie...e of the Karolinska,Institutet. The research links...
(Date:10/2/2008)... Data Indicate Dual Modes of Action and Synergy...rstCall/ -- Access Pharmaceuticals, Inc.,(OTC Bull...eclinical,studies on Angiolix showing that by bloc...enic effect as well as a direct anti-proliferative...s of human breast cancer (MX-1),Angiolix had a si...
(Date:10/1/2008)...ta support the therapeutic potential of Amylin,s i...to obesity pharmacotherapy, SAN DIEGO, Oct. 1 /PR.... (Nasdaq: AMLN ) today announced that new data f...ed at the 2008 Annual Scientific Meeting of The,Ob...Society,s annual,meeting is one of the largest and...
(Date:10/1/2008)...Intermezzo(R) (zolpidem tartrate sublingual lozeng...ly for use in the middle of the night when ...sleep, PT. RICHMOND, Calif., Oct. 1 /PRNewswire/ ...ld specialty pharmaceutical company, announced tod...DA) to the U.S. Food and,Drug Administration (FDA)...
Breaking Medicine Technology:Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 2Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 3Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 4Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 6Experts discuss climate change during UH lecture series 5081 1Experts discuss climate change during UH lecture series 5081 2Telik Announces Receipt of Nasdaq Notice 7927 1Telik Announces Receipt of Nasdaq Notice 7927 2Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment 7926 1Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment 7926 2Army can boost mission success by better managing 5076 1Army can boost mission success by better managing 5076 2Army can boost mission success by better managing 5076 3Army can boost mission success by better managing 5076 4
...trates Continued Safety for XIENCE V with No,Late ...ac Events,Out to Three Years, BARCELONA, Spain, Ma...ta from the SPIRIT FIRST trial demonstrated no,add...o late stent,thrombosis in patients treated with e...onary Stent System or its MULTI-LINK,VISION(R) met...
...2007 /PRNewswire-FirstCall/ -- Forest,Laboratories...d,that preliminary top-line results from a 1,196 p...ebo-controlled pivotal Phase III,study demonstrate...milnacipran as a treatment of fibromyalgia syndrom...to review initial top-line,results and further ana...
Other Medicine Technology:Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 2Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 3Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 6
...) is the sulfate ester of DHEA, derived from sulfa... in adrenal and extradrenal tissues. DHEA is the m...nd is a precursor for testosterone and estrogen bi...nic activity, which for unsulfated DHEA has been e...
...ompetition principle and the microplate separation...e and a fixed amount of DHEA-S conjugated with hor... of a polyclonal DHEA-S antiserum coated onto the ...te is washed to stop the competition reaction. Hav...
Inquire
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM.
Medicine Products: